Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Cytosorbents (CTSO) over the last 15 years, with Q3 2025 value amounting to $3.0 million.

  • Cytosorbents' Accounts Payables rose 2980.39% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 million, marking a year-over-year increase of 2980.39%. This contributed to the annual value of $3.3 million for FY2024, which is 1215.54% down from last year.
  • As of Q3 2025, Cytosorbents' Accounts Payables stood at $3.0 million, which was up 2980.39% from $3.4 million recorded in Q2 2025.
  • Cytosorbents' 5-year Accounts Payables high stood at $4.8 million for Q1 2022, and its period low was $1.7 million during Q4 2022.
  • Over the past 5 years, Cytosorbents' median Accounts Payables value was $3.0 million (recorded in 2023), while the average stood at $2.9 million.
  • Over the last 5 years, Cytosorbents' Accounts Payables had its largest YoY gain of 18766.41% in 2022, and its largest YoY loss of 4099.7% in 2022.
  • Cytosorbents' Accounts Payables (Quarter) stood at $2.8 million in 2021, then plummeted by 41.0% to $1.7 million in 2022, then skyrocketed by 129.71% to $3.8 million in 2023, then dropped by 12.16% to $3.3 million in 2024, then dropped by 9.13% to $3.0 million in 2025.
  • Its Accounts Payables stands at $3.0 million for Q3 2025, versus $3.4 million for Q2 2025 and $3.3 million for Q1 2025.